Morphogenesis, Inc. Is Developing a Cell and Gene Therapy Focusing on a Cancer Vaccine Immunotherapy That Uses the Body’s Own Immune System to Kill Solid Tumors (CEO CFO Magazine)

Morphogenesis, Inc. Is Developing a Cell and Gene Therapy Focusing on a Cancer Vaccine Immunotherapy That Uses the Body’s Own Immune System to Kill Solid Tumors

Dr. Patricia Lawman, CEO and co-founder of UF startup Morphogenesis, Inc., a clinical-stage immunotherapy company headquartered in Tampa, talks about the company, their projects – current and future – and the challenges she and her team have to face while developing cell and gene therapy technologies.

“We are currently focusing on our cancer vaccine. This is an immunotherapy where we simply take a gene that encodes a bacterial protein that is highly immunogenic. We put this gene into a patient’s tumor cells and because there is a proprietary sequence within this protein, it is actually expressed on the surface of the tumor cell where it acts like a big red flag to the immune system” she said.

Learn more about Morphogenesis, Inc. Is Developing a Cell and Gene Therapy Focusing on a Cancer Vaccine Immunotherapy That Uses the Body’s Own Immune System to Kill Solid Tumors.
X